Back to Results
First PageMeta Content
Incontinence / Overactive bladder / Muscarinic antagonists / Solifenacin / Astellas Pharma / Urinary incontinence / Urge incontinence / Urinary bladder / Frequent urination / Medicine / Urology / Anatomy


June 1, 2006 Astellas Launches “Vesicare®” for the treatment of Overactive Bladder in Japan Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced that Vesicar
Add to Reading List

Document Date: 2008-09-19 00:56:17

Open Document

File Size: 24,34 KB

Share Result on Facebook

City

Tokyo / /

Company

Japan Astellas Pharma Inc. / Astellas Pharma Inc. / /

Continent

Europe / /

Country

Japan / United States / /

Currency

JPY / /

Event

FDA Phase / /

/

MedicalCondition

Overactive Bladder / urge incontinence / urinary incontinence / contraction of smooth muscles / /

Person

Toichi Takenaka / /

/

Position

President and CEO / /

Product

Vesicare / 5mg / Vesicare® / /

URL

http /

SocialTag